Alteration of early dendritic cell activation by cancer cell lines predispose immunosuppression, which cannot be reversed by TLR4 stimulation | Zendy

Ying Kong | Zendy; Martina Fuchsberger | Zendy; Magdalena Plebanski | Zendy; Vasso Apostolopoulos | Zendy

Open Access

Alteration of early dendritic cell activation by cancer cell lines predispose immunosuppression, which cannot be reversed by TLR4 stimulation

Author(s) -

Ying Kong,

Martina Fuchsberger,

Magdalena Plebanski,

Vasso Apostolopoulos

Publication year - 2016

Publication title -

acta biochimica et biophysica sinica

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.771

H-Index - 57

eISSN - 1745-7270

pISSN - 1672-9145

DOI - 10.1093/abbs/gmw102

Subject(s) - cd80 , cancer immunotherapy , dendritic cell , cancer , cancer cell , cancer research , immunotherapy , immunology , cd86 , granulocyte macrophage colony stimulating factor , colony stimulating factor , cytokine , biology , immune system , medicine , t cell , microbiology and biotechnology , haematopoiesis , cytotoxic t cell , cd40 , stem cell , in vitro , biochemistry

Dendritic cells (DCs) have shown promise for use in cancer vaccine and cancer immunotherapy studies. However, we demonstrate that cancer cell lines can negatively interfere with DC generation in granulocyte-macrophage colony-stimulating factor (GM-CSF)-derived cultures, although cancer cells are able to enhance CD80 cell surface activation marker and cytokine secretion. Furthermore, in the presence of cancer cells, GM-CSF-derived DCs are unable to stimulate T-cells. Additional stimulation with toll-like receptor 4 cannot fully reverse the suppressive effect of cancer cells or supernatant. Hence, it is imperative to understand the immunosuppressive effects of cancer on DCs in order for DC-based cancer immunotherapy to be successful.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research